Abstract
Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
Keywords: Calcium antagonist, coronary artery disease, ranolazine, stable angina, β-blockers, nitrogen.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:New Anti-Anginal Drugs: Ranolazine
Volume: 13 Issue: 1
Author(s): Chiara Cavallino, Manuela Facchini, Alessia Veia, Sara Bacchni, Andrea Rognoni, Francesco Rametta, Alessandro Lupi and Angelo S. Bongo
Affiliation:
Keywords: Calcium antagonist, coronary artery disease, ranolazine, stable angina, β-blockers, nitrogen.
Abstract: Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
Export Options
About this article
Cite this article as:
Cavallino Chiara, Facchini Manuela, Veia Alessia, Bacchni Sara, Rognoni Andrea, Rametta Francesco, Lupi Alessandro and Bongo S. Angelo, New Anti-Anginal Drugs: Ranolazine, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/1871525713666141219112841
DOI https://dx.doi.org/10.2174/1871525713666141219112841 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Dietary Compounds, Epigenetic Modifications and Metabolic Diseases
Current Chemical Biology Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design The Coronin Family and Human Disease
Current Protein & Peptide Science Use of Grape Polyphenols for Promoting Human Health: A Review of Patents
Recent Patents on Food, Nutrition & Agriculture A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Atherosclerosis and Inflammation: Insight from Carotid and Intracoronary Ultrasound Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
Current Pharmaceutical Design Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry